Selected research
Market Structure
Global Neuroleptic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Neuroleptic market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Neuroleptic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Neuroleptic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Neuroleptic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Neuroleptic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Neuroleptic include Johnson & Johnso, Eli Lilly, Pfizer, GlaxoSmithKline and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Neuroleptic market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Neuroleptic and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Neuroleptic sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuroleptic market size, projected growth trends, production technologies, key applications, and end-use industries.
Neuroleptic Segment by Company
Johnson & Johnso
Eli Lilly
Pfizer
GlaxoSmithKline
Bristol-Myers Squibb
Neuroleptic Segment by Type
Droperidol
Midazolam
Neuroleptic Segment by Application
Medical Care
Scientific Research
Others
Neuroleptic Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroleptic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuroleptic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroleptic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Neuroleptic market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuroleptic manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neuroleptic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Neuroleptic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Droperidol
- Midazolam
Applications
- Medical Care
- Scientific Research
- Others
Companies covered
- Johnson & Johnso
- Eli Lilly
- Pfizer
- GlaxoSmithKline
- Bristol-Myers Squibb
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Neuroleptic Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Neuroleptic Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Neuroleptic Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Neuroleptic Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Neuroleptic Market Dynamics
- 2.1 Neuroleptic Industry Trends
- 2.2 Neuroleptic Industry Drivers
- 2.3 Neuroleptic Industry Opportunities and Challenges
- 2.4 Neuroleptic Industry Restraints
3 Neuroleptic Market by Manufacturers
- 3.1 Global Neuroleptic Revenue by Manufacturers (2021-2026)
- 3.2 Global Neuroleptic Sales by Manufacturers (2021-2026)
- 3.3 Global Neuroleptic Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Neuroleptic Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Neuroleptic Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Neuroleptic Manufacturers, Product Type & Application
- 3.7 Global Neuroleptic Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Neuroleptic Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Neuroleptic Players Market Share by Revenue in 2025
- 3.8.3 2025 Neuroleptic Tier 1, Tier 2, and Tier 3
4 Neuroleptic Market by Type
- 4.1 Neuroleptic Type Introduction
- 4.1.1 Droperidol
- 4.1.2 Midazolam
- 4.2 Global Neuroleptic Sales by Type
- 4.2.1 Global Neuroleptic Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Neuroleptic Sales by Type (2021-2032)
- 4.2.3 Global Neuroleptic Sales Market Share by Type (2021-2032)
- 4.3 Global Neuroleptic Revenue by Type
- 4.3.1 Global Neuroleptic Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Neuroleptic Revenue by Type (2021-2032)
- 4.3.3 Global Neuroleptic Revenue Market Share by Type (2021-2032)
5 Neuroleptic Market by Application
- 5.1 Neuroleptic Application Introduction
- 5.1.1 Medical Care
- 5.1.2 Scientific Research
- 5.1.3 Others
- 5.2 Global Neuroleptic Sales by Application
- 5.2.1 Global Neuroleptic Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Neuroleptic Sales by Application (2021-2032)
- 5.2.3 Global Neuroleptic Sales Market Share by Application (2021-2032)
- 5.3 Global Neuroleptic Revenue by Application
- 5.3.1 Global Neuroleptic Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Neuroleptic Revenue by Application (2021-2032)
- 5.3.3 Global Neuroleptic Revenue Market Share by Application (2021-2032)
6 Global Neuroleptic Sales by Region
- 6.1 Global Neuroleptic Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Neuroleptic Sales by Region (2021-2032)
- 6.2.1 Global Neuroleptic Sales by Region (2021-2026)
- 6.2.2 Global Neuroleptic Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Neuroleptic Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Neuroleptic Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Neuroleptic Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Neuroleptic Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Neuroleptic Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Neuroleptic Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Neuroleptic Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Neuroleptic Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Neuroleptic Revenue by Region
- 7.1 Global Neuroleptic Revenue by Region
- 7.1.1 Global Neuroleptic Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Neuroleptic Revenue by Region (2021-2026)
- 7.1.3 Global Neuroleptic Revenue by Region (2027-2032)
- 7.1.4 Global Neuroleptic Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Neuroleptic Revenue (2021-2032)
- 7.2.2 North America Neuroleptic Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Neuroleptic Revenue (2021-2032)
- 7.3.2 Europe Neuroleptic Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Neuroleptic Revenue (2021-2032)
- 7.4.2 Asia-Pacific Neuroleptic Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Neuroleptic Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Neuroleptic Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Johnson & Johnso
- 8.1.1 Johnson & Johnso Company Information
- 8.1.2 Johnson & Johnso Business Overview
- 8.1.3 Johnson & Johnso Neuroleptic Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Johnson & Johnso Neuroleptic Product Portfolio
- 8.1.5 Johnson & Johnso Recent Developments
- 8.2 Eli Lilly
- 8.2.1 Eli Lilly Company Information
- 8.2.2 Eli Lilly Business Overview
- 8.2.3 Eli Lilly Neuroleptic Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Eli Lilly Neuroleptic Product Portfolio
- 8.2.5 Eli Lilly Recent Developments
- 8.3 Pfizer
- 8.3.1 Pfizer Company Information
- 8.3.2 Pfizer Business Overview
- 8.3.3 Pfizer Neuroleptic Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Pfizer Neuroleptic Product Portfolio
- 8.3.5 Pfizer Recent Developments
- 8.4 GlaxoSmithKline
- 8.4.1 GlaxoSmithKline Company Information
- 8.4.2 GlaxoSmithKline Business Overview
- 8.4.3 GlaxoSmithKline Neuroleptic Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 GlaxoSmithKline Neuroleptic Product Portfolio
- 8.4.5 GlaxoSmithKline Recent Developments
- 8.5 Bristol-Myers Squibb
- 8.5.1 Bristol-Myers Squibb Company Information
- 8.5.2 Bristol-Myers Squibb Business Overview
- 8.5.3 Bristol-Myers Squibb Neuroleptic Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Bristol-Myers Squibb Neuroleptic Product Portfolio
- 8.5.5 Bristol-Myers Squibb Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Neuroleptic Value Chain Analysis
- 9.1.1 Neuroleptic Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Neuroleptic Production Mode & Process
- 9.2 Neuroleptic Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Neuroleptic Distributors
- 9.2.3 Neuroleptic Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst